| Baseline | Week 12 | Week 24 |
|---|
| |
|---|
| golimumab (n=40) | placebo (n=20) | p | golimumab (n=40) | placebo (n=20) | p | golimumab (n=40) | placebo (n=20) | p |
|---|
|
|---|
| TJC | 5.0 (3.0, 7.5) | 4.0 (2.0, 12.0) | 0.84 | 0 (0.0, 3.0) | 4.5 (1.0, 11.5) | 0.0011 | 0.0 (0.0, 2.0) | 5.0 (1.0, 7.5) | 0.0006 |
| SJC | 4.0 (2.5, 5.5) | 3.0 (2.0, 6.0) | 0.46 | 0.0 (0.0,1.0) | 2.5 (0.5, 7.0) | 0.0003 | 0.0 (0.0, 0.0) | 1.5 (0.0, 6.0) | 0.0004 |
| CRP | 1.06 (0.34, 3.38) | 1.68 (0.48, 4.87) | 0.43 | 0.12 (0.06, 0.24) | 0.72 (0.17, 2.03) | 0.0009 | 0.10 (0.06, 0.24) | 0.65 (0.15, 0.85) | 0.0043 |
| ESR | 21.5 (8.5, 41.5) | 28.0 (11.0, 60.0) | 0.45 | 3.0 (2.0, 6.0) | 17.5 (4.0, 31.0) | 0.0016 | 3.0 (2.0, 8.0) | 8.5 (4.0, 21.0) | 0.0244 |
| BASDAI | 5.25 (4.00, 6.30) | 6.05 (4.50, 6.80) | 0.27 | 2.20 ( 1.05, 3.50 ) | 6.30 (2.75, 6.75) | 0.0006 | 1.55 (0.20, 2.40) | 6.00 (2.00, 6.95) | 0.0002 |
| BASFI | 3.60 (2.35, 5.30) | 4.90 (3.35, 6.95) | 0.08 | 1.20 (0.40, 2.60) | 5.40 ( 1.95, 6.50) | 0.0006 | 0.80 (0.05, 1.85) | 5.05 (2.05, 6.35) | <.0001 |
| Response criteria |
| pSpARC 40% | | | | 23 (57.5%) | 4 (20%) | 0.0069 | 20 (50%) | 3 (15%) | 0.0112 |
| pSpARC 50% | | | | 22 (55%) | 4 (20% | 0.0132 | 22 (55%) | 3 (15%) | 0.0048 |
| pSpARC 70% | | | | 20 (50%) | 3 (15%) | 0.0112 | 16 (40%) | 3 (15%) | 0.0768 |
| ASAS 20 respons | | | | 25 (62.5%) | 3 (15%) | 0.0008 | 27 (67.5%) | 6 (30%) | 0.0122 |
| ASAS 40 respons | | | | 19 (47.5%) | 3 (15%) | 0.0219 | 26 (65%) | 3 (15%) | 0.0003 |